COSCIENS Biopharma Inc. (CSCI)
NASDAQ: CSCI · Real-Time Price · USD
3.700
-0.040 (-1.07%)
Oct 8, 2024, 4:00 PM EDT - Market closed
COSCIENS Biopharma Revenue
COSCIENS Biopharma had revenue of $2.34M in the quarter ending June 30, 2024, with 4.05% growth. This brings the company's revenue in the last twelve months to $4.92M, down -43.63% year-over-year. In the year 2023, COSCIENS Biopharma had annual revenue of $4.50M, down -20.25%.
Revenue (ttm)
$4.92M
Revenue Growth
-43.63%
P/S Ratio
n/a
Revenue / Employee
$409,583
Employees
12
Market Cap
14.96M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 4.50M | -1.14M | -20.25% |
Dec 31, 2022 | 5.64M | 380.00K | 7.22% |
Dec 31, 2021 | 5.26M | 1.61M | 44.03% |
Dec 31, 2020 | 3.65M | 3.12M | 586.47% |
Dec 31, 2019 | 532.00K | -26.35M | -98.02% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Cutera | 169.19M |
Cara Therapeutics | 11.00M |
Evogene | 9.45M |
HCW Biologics | 3.92M |
Alterity Therapeutics | 2.68M |
Lyra Therapeutics | 1.82M |
AIM ImmunoTech | 201.00K |
CSCI News
- 12 hours ago - COSCIENS Biopharma Announces Change to Board of Directors - GlobeNewsWire
- 7 days ago - COSCIENS Biopharma Announces Appointment of Pierre Labbé as Director - GlobeNewsWire
- 15 days ago - COSCIENS Biopharma Inc. Provides Updates on Merger Integration, Management Succession Plans and Ongoing Development Programs - GlobeNewsWire
- 6 weeks ago - COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency - GlobeNewsWire
- 2 months ago - COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results - GlobeNewsWire
- 2 months ago - Aeterna Zentaris Inc. Announces Name Change to COSCIENS Biopharma Inc. - GlobeNewsWire
- 3 months ago - Aeterna Zentaris Announces Results of Virtual 2024 Meeting of Shareholders - GlobeNewsWire
- 4 months ago - Aeterna Zentaris Announces Last Patient Last Visit in Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency - GlobeNewsWire